Sibutramine is the first slimming drug approved by SDA (State Administration of Medical Supplies) and listed in China. It has a world-leading technology and a unique dual-action mechanism. In the past 30 years, only two drugs, sibutramine and orlistat, were approved by the FDA in June19971and officially listed in the United States in February 1998. Sibutramine has been identified as the first choice for weight loss by European CPMP (Monopoly Drug Committee). The main function of sibutramine hydrochloride is suitable for the treatment of obesity, including diet control, exercise failure and weight control, including weight loss and weight loss maintenance. Treatment should be combined with low calorie and exercise. It is suggested to treat obese patients with body mass index ≥30kg/m2 or ≥27kg/m2 (accompanied by other risk factors such as hypertension, diabetes and dyslipidemia). ). The calculation of body mass index (BMI) of Qumei diet pills: weight (kg) divided by the square value of height (m) (kg/m2). For example: weight 100, height 1.8m, body mass index =100/(1.80) 2 =100/3.24 = 30.9. The recommended starting dose is 10mg once a day, which can be taken alone or with food in the morning. If the weight loss is insufficient, the dose can be adjusted to 15mg per day after 4 weeks. If the patient can't stand the dose of 10mg, it can be reduced to 5mg. Dose should be adjusted according to the patient's blood pressure and heart rate. Doses exceeding15mg/day are not recommended. Adverse reactions 1. Common adverse reactions are: dry mouth, anorexia, insomnia, constipation and so on. 2. Other adverse reactions with incidence ≥ 1% include fever, increased heart rate, elevated blood pressure, dyspnea, diarrhea and gastroenteritis. 3. This product can cause abnormal liver function, which often disappears with further treatment, and has a clear dose-response relationship. 4. Visible limb spasms, increased tension, abnormal thinking, seizures, interstitial nephritis, menstrual disorder and peripheral edema; 5. Arthritis, itchy skin, abnormal sensation, amblyopia and other reactions. Precautions 1. The treatment of obesity should focus on diet control and exercise. 2. Obesity caused by Cushing's syndrome and hypothyroidism should be excluded from the application scope of this product. 3. Patients with a history of hypertension should be used with caution. 4. Because it may increase or aggravate the formation of gallstones, patients with gallstones should use this product with caution. 5. This product can cause pupil dilation, so patients with angle-closure glaucoma should use it with caution. 6. Patients with a history of epilepsy should use it with caution, and patients with epilepsy should stop using it. 7. It may affect judgment, thinking or motor skills. Taboo 1. Patients receiving monoamine oxidase inhibitor (MAOI) therapy. 2. Patients receiving other central appetite suppressants. 3. Patients with anorexia nervosa. 4. Patients who are allergic to the ingredients of this product. 5. Hypertensive patients whose blood pressure cannot be controlled or is not well controlled. 6. Patients with coronary heart disease, heart failure, arrhythmia and stroke. 7. Patients with severe hepatic and renal insufficiency. 8. Animal experiments have observed that this product has teratogenic effect, but no carcinogenic or mutagenic effect has been observed. It is recommended that pregnant women or pregnant women and lactating women do not take this product.